SLC1A2 and Parkinson disease: Cef has been revealed to selectively increase GLT-1 expression and uptake activity, and this upregulation has been suggested to be protective in many models of diseases, such as amyotrophic lateral sclerosis (Rothstein et al., 2005) and Parkinson’s disease (Hsu et al., 2015; Hsieh et al., 2017).